Study Confirms Elucid’s AI Software Accurately Estimates Lesion-Specific Ischemia Compared to Standard of Care
Elucid, a medical technology company developing AI software to enable cardiovascular disease detection, announced today the publication of new clinical data in the International Journal of Cardiology. The study, entitled “Coronary plaque assessment of Vasodilative capacity by CT angiography effectively estimates fractional flow reserve”demonstrates that Fractional Flow Reserve (FFR) assessment derived from non-invasive plaque morphology using Elucid’s software is highly accurate as compared to invasive FFR.
Biologic therapy for psoriasis may reduce heart disease, reveals study
Patients with psoriasis treated with biologic therapy, which are protein-based infusions to suppress inflammation, had a significant reduction in Lipid-Rich Necrotic Core plaque in coronary arteries over one year, as measured by vascuCAP. The research was published in Circulation: Cardiovascular Imaging, an American Heart Association journal.
Unveiling an AI-driven risk stratification tool to attain better stroke prediction
It’s one of the most intractable areas of focus in all of vascular disease, and the source of—inarguably, Brajesh K. Lal, MD, emphasizes—the most intensely studied vascular surgical procedure anywhere in the sphere of the specialty. And for some years, Lal has had the development of a more accurate method of risk assessment for this perennial vascular problem fixed firmly in his sights: carotid disease.
Elucid Bioimaging Inc. has already gained an FDA clearance and a CE mark for its Vascucap artificial intelligence-based software that analyzes CT angiograms (CTA) to characterize and quantify atherosclerotic plaque to predict a patient’s stroke risk. But recent interim data presented on July 2, 2020, at the Society for Vascular Surgery conference found that the AI algorithm is more effective than standard-of-care diagnostics.
Boston-based medical technology company Elucid Bio, maker of the Food and Drug Administration (FDA)-cleared and CE-marked vascuCAP software, announced Wednesday, July 1, that its novel artificial intelligence (AI) technology demonstrated a significant improvement in accuracy of stroke prediction as compared to stenosis-based guidelines over a six-year time period.
July 1, 2020—Elucid Bio, manufacturer of the vascuCAP software, announced that its artificial intelligence (AI) technology demonstrated a significant improvement in the accuracy of stroke prediction compared with a stenosis-based approach to risk-stratification during a 6-year period in the CRISP Consortium study of carotid risk prediction.
Elucid Bio, maker of the FDA-cleared and CE-marked vascuCAP® software, announced today that its novel artificial intelligence (AI) technology demonstrated a significant improvement in accuracy of stroke prediction as compared to stenosis-based guidelines over a six-year time period. The interim results of the CRISP trial will be presented on Thursday, July 2, during Scientific Session 9 at the Society for Vascular Surgery conference, SVS Online Summer 2020.
Boston, Massachusetts - Feb 17, 2020 - A leading software company called Elucid Bioimaging believes it can. Approximately 1.5 million Americans have a heart attack or stroke each year. They are the two leading causes of death in developed countries around the world, but do we have an opportunity to improve our ability to predict these events? And can we deliver personalized treatment to prevent them?